A/H5N1/LT Dose Ranging Study

Summary

This is a Phase 2, randomized, blinded, clinical trial. Up to 500 eligible subjects will be enrolled and randomized in a 1:2:2:1:2:2 ratio into one of six groups, and vaccinated in this study. Subjects will receive an intramuscular injection of the influenza A/H5N1 (low or high dose) on Day 0 with or without a patch (low or high dose).

Timeline

Start

2009-05

Primary completion

2010-01

Completion

2011-07

Drugs

Indications